心房颤动合并心力衰竭患者抗凝药物的应用

摘要

The interaction between atrial fibrillation (AF) and heart failure (HF) and following poor prognosis re-ceive more and more attention.Currently,there are four kinds of new oral anticoagulants (NOACs) that can pre-vent thromboembolism caused by AF.More and more evidence support that they can be used in AF + HF patients,including valvular,non-valvular AF or patients undergoing direct current cardioversion.The present article aimed at discussing possibility of NOACs application in AF + HF patients.%心房颤动与心力衰竭之间的相互作用及其带来的不良预后越来越受人重视.目前有四种新型口服抗凝药物(NOACs)可以预防由心房颤动导致的血栓栓塞.越来越多的心房颤动伴发心力衰竭的患者,包括瓣膜性、非瓣膜性房颤或者应用直流电复律治疗的患者.本文旨在讨论NOACs在心房颤动合并心力衰竭中应用的可能性.